Latigo Biotherapeutics, Inc. (LTGO) insider trading.
In Q3 2026, insiders at Latigo Biotherapeutics, Inc. reported 34 non-derivative transactions on 20 Forms 3, 4 and 5: 2 open-market purchases worth $5.0M and 0 sales.
- Transactions
- 34
- Purchases (P)
- 2
- Sales (S)
- 0
- Net shares, P minus S
- 280,000
- Insiders
- 6
- Last filed
- 2026-08-12
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Foresite Capital Fund VI LP / Foresite Capital Opportunity Fund V, L.P. / Foresite Capital Fund V, L.P. / Foresite Capital Management VI LLC / Foresite Capital Management V, LLC / Foresite Capital Opportunity Management V, LLC | TenPercentOwner | 8 | 1 | 0 |
| Tananbaum James B. | Director, TenPercentOwner | 8 | 1 | 0 |
| Westlake BioPartners GP I, LLC / Westlake BioPartners Fund I, L.P. / Westlake BioPartners GP II, LLC / Westlake BioPartners Opportunity Fund I, L.P. / Westlake BioPartners Opportunity GP I, LLC / Westlake BioPartners Fund II, L.P. | TenPercentOwner | 7 | 0 | 0 |
| Seidenberg Beth C | Director, TenPercentOwner | 7 | 0 | 0 |
| Sanofi | TenPercentOwner | 2 | 0 | 0 |
| 5AM Partners VI, LLC / 5AM Ventures VI, L.P. / Schwab Andrew J. / 5AM Opportunities II (GP), LLC / 5AM Opportunities II, L.P. / PARMAR KUSH | TenPercentOwner | 2 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-10 | Sanofi | C (A) | 494,800 | — | 494,800 | Form 4 |
| 2026-08-10 | Sanofi | C (A) | 177,978 | — | 672,788 | Form 4 |
| 2026-08-10 | 5AM Partners VI, LLC / 5AM Ventures VI, L.P. / Schwab Andrew J. / 5AM Opportunities II (GP), LLC / 5AM Opportunities II, L.P. / PARMAR KUSH | C (A) | 2,350,419 | — | 2,350,419 | Form 4 |
| 2026-08-10 | 5AM Partners VI, LLC / 5AM Ventures VI, L.P. / Schwab Andrew J. / 5AM Opportunities II (GP), LLC / 5AM Opportunities II, L.P. / PARMAR KUSH | C (A) | 4,975,543 | — | 4,975,543 | Form 4 |
| 2026-08-10 | Westlake BioPartners GP I, LLC / Westlake BioPartners Fund I, L.P. / Westlake BioPartners GP II, LLC / Westlake BioPartners Opportunity Fund I, L.P. / Westlake BioPartners Opportunity GP I, LLC / Westlake BioPartners Fund II, L.P. | C (A) | 938,979 | — | 1,368,532 | Form 4 |
| 2026-08-10 | Westlake BioPartners GP I, LLC / Westlake BioPartners Fund I, L.P. / Westlake BioPartners GP II, LLC / Westlake BioPartners Opportunity Fund I, L.P. / Westlake BioPartners Opportunity GP I, LLC / Westlake BioPartners Fund II, L.P. | C (A) | 3,547,842 | — | 4,916,374 | Form 4 |
| 2026-08-10 | Westlake BioPartners GP I, LLC / Westlake BioPartners Fund I, L.P. / Westlake BioPartners GP II, LLC / Westlake BioPartners Opportunity Fund I, L.P. / Westlake BioPartners Opportunity GP I, LLC / Westlake BioPartners Fund II, L.P. | C (A) | 2,066,857 | — | 2,094,813 | Form 4 |
| 2026-08-10 | Westlake BioPartners GP I, LLC / Westlake BioPartners Fund I, L.P. / Westlake BioPartners GP II, LLC / Westlake BioPartners Opportunity Fund I, L.P. / Westlake BioPartners Opportunity GP I, LLC / Westlake BioPartners Fund II, L.P. | C (A) | 165,519 | — | 5,160,847 | Form 4 |
| 2026-08-10 | Westlake BioPartners GP I, LLC / Westlake BioPartners Fund I, L.P. / Westlake BioPartners GP II, LLC / Westlake BioPartners Opportunity Fund I, L.P. / Westlake BioPartners Opportunity GP I, LLC / Westlake BioPartners Fund II, L.P. | C (A) | 1,027,635 | — | 5,944,009 | Form 4 |
| 2026-08-10 | Westlake BioPartners GP I, LLC / Westlake BioPartners Fund I, L.P. / Westlake BioPartners GP II, LLC / Westlake BioPartners Opportunity Fund I, L.P. / Westlake BioPartners Opportunity GP I, LLC / Westlake BioPartners Fund II, L.P. | C (A) | 3,464,072 | — | 3,510,927 | Form 4 |
| 2026-08-10 | Westlake BioPartners GP I, LLC / Westlake BioPartners Fund I, L.P. / Westlake BioPartners GP II, LLC / Westlake BioPartners Opportunity Fund I, L.P. / Westlake BioPartners Opportunity GP I, LLC / Westlake BioPartners Fund II, L.P. | C (A) | 1,484,401 | — | 4,995,328 | Form 4 |
| 2026-08-10 | Foresite Capital Fund VI LP / Foresite Capital Opportunity Fund V, L.P. / Foresite Capital Fund V, L.P. / Foresite Capital Management VI LLC / Foresite Capital Management V, LLC / Foresite Capital Opportunity Management V, LLC | C (A) | 195,776 | — | 2,203,800 | Form 4 |
| 2026-08-10 | Foresite Capital Fund VI LP / Foresite Capital Opportunity Fund V, L.P. / Foresite Capital Fund V, L.P. / Foresite Capital Management VI LLC / Foresite Capital Management V, LLC / Foresite Capital Opportunity Management V, LLC | P (A) | 140,000 | $18 | 2,008,024 | Form 4 |
| 2026-08-10 | Foresite Capital Fund VI LP / Foresite Capital Opportunity Fund V, L.P. / Foresite Capital Fund V, L.P. / Foresite Capital Management VI LLC / Foresite Capital Management V, LLC / Foresite Capital Opportunity Management V, LLC | C (A) | 742,201 | $0 | 1,868,024 | Form 4 |
| 2026-08-10 | Foresite Capital Fund VI LP / Foresite Capital Opportunity Fund V, L.P. / Foresite Capital Fund V, L.P. / Foresite Capital Management VI LLC / Foresite Capital Management V, LLC / Foresite Capital Opportunity Management V, LLC | C (A) | 1,125,823 | $0 | 1,125,823 | Form 4 |
| 2026-08-10 | Foresite Capital Fund VI LP / Foresite Capital Opportunity Fund V, L.P. / Foresite Capital Fund V, L.P. / Foresite Capital Management VI LLC / Foresite Capital Management V, LLC / Foresite Capital Opportunity Management V, LLC | C (A) | 445,320 | $0 | 3,562,984 | Form 4 |
| 2026-08-10 | Foresite Capital Fund VI LP / Foresite Capital Opportunity Fund V, L.P. / Foresite Capital Fund V, L.P. / Foresite Capital Management VI LLC / Foresite Capital Management V, LLC / Foresite Capital Opportunity Management V, LLC | C (A) | 3,117,664 | $0 | 3,117,664 | Form 4 |
| 2026-08-10 | Foresite Capital Fund VI LP / Foresite Capital Opportunity Fund V, L.P. / Foresite Capital Fund V, L.P. / Foresite Capital Management VI LLC / Foresite Capital Management V, LLC / Foresite Capital Opportunity Management V, LLC | C (A) | 3,117,664 | $0 | 3,117,664 | Form 4 |
| 2026-08-10 | Foresite Capital Fund VI LP / Foresite Capital Opportunity Fund V, L.P. / Foresite Capital Fund V, L.P. / Foresite Capital Management VI LLC / Foresite Capital Management V, LLC / Foresite Capital Opportunity Management V, LLC | C (A) | 296,880 | $0 | 3,414,544 | Form 4 |
| 2026-08-10 | Seidenberg Beth C | C (A) | 2,066,857 | — | 2,094,813 | Form 4 |
| 2026-08-10 | Seidenberg Beth C | C (A) | 165,519 | — | 5,160,847 | Form 4 |
| 2026-08-10 | Seidenberg Beth C | C (A) | 1,484,401 | — | 4,995,328 | Form 4 |
| 2026-08-10 | Seidenberg Beth C | C (A) | 3,464,072 | — | 3,510,927 | Form 4 |
| 2026-08-10 | Seidenberg Beth C | C (A) | 1,027,635 | — | 5,944,009 | Form 4 |
| 2026-08-10 | Seidenberg Beth C | C (A) | 938,979 | — | 1,368,532 | Form 4 |
| 2026-08-10 | Seidenberg Beth C | C (A) | 3,547,842 | — | 4,916,374 | Form 4 |
| 2026-08-10 | Tananbaum James B. | C (A) | 3,117,664 | — | 3,117,664 | Form 4 |
| 2026-08-10 | Tananbaum James B. | C (A) | 195,776 | — | 2,203,800 | Form 4 |
| 2026-08-10 | Tananbaum James B. | P (A) | 140,000 | $18 | 2,008,024 | Form 4 |
| 2026-08-10 | Tananbaum James B. | C (A) | 742,201 | — | 1,868,024 | Form 4 |
| 2026-08-10 | Tananbaum James B. | C (A) | 1,125,823 | — | 1,125,823 | Form 4 |
| 2026-08-10 | Tananbaum James B. | C (A) | 296,880 | — | 3,414,544 | Form 4 |
| 2026-08-10 | Tananbaum James B. | C (A) | 445,320 | — | 3,562,984 | Form 4 |
| 2026-08-10 | Tananbaum James B. | C (A) | 3,117,664 | — | 3,117,664 | Form 4 |
Transaction codes in this quarter
Get LTGO insider transactions through the API
Request with your API key
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=2056611&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · LTGO company page · Latigo Biotherapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Latigo Biotherapeutics, Inc. (LTGO)?
In Q3 2026, insiders at Latigo Biotherapeutics, Inc. reported 34 non-derivative transactions on 20 Forms 3, 4 and 5: 2 open-market purchases worth $5.0M and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Latigo Biotherapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Source: SEC Insider Transactions Data Sets, Q3 2026, retrieved 2026-10-27. Footnotes, derivative holdings and amendments are in the linked filings. Not investment advice.
Plain-text version for agents and LLMs: /insider-trading/ltgo.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.